Skip to main content
Fig. 2 | BMC Immunology

Fig. 2

From: Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program

Fig. 2

Anti-VEGF IgG seroconversion study and serum blocking activity in vaccinated patients during the re-immunization phase. a Seroconverted patients (individual that has shown two or more samples positive for VEGF-specific IgG antibodies). b Blocking activities on VEGF/VEGFR2 or VEGF/VEGFR1 bindings. Patients that has shown at least one serum sample with neutralizing anti-VEGF antibodies were considered with a positive blocking activity

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us